This gives a first indication why ELISA assays targeting full‐length Ng had a similar power for distinguishing AD from control samples as those assays targeting both full‐length Ng and its C‐terminal peptides (Willemse et al., 2018). The gene discussed is NRGN; the disease is Alzheimer disease.